Top-Rated Stocks NASDAQ:DICE DICE Therapeutics - DICE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $27.46 +0.25 (+0.92%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$26.94▼$27.7950-Day Range$26.05▼$32.3152-Week Range$12.64▼$45.99Volume443,657 shsAverage Volume467,467 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$65.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DICE Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside139.8% Upside$65.86 Price TargetShort InterestBearish17.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 16 Articles This WeekInsider TradingAcquiring Shares$8.29 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.70) to ($3.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector761st out of 995 stocksPharmaceutical Preparations Industry370th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingDICE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.86, DICE Therapeutics has a forecasted upside of 139.8% from its current price of $27.46.Amount of Analyst CoverageDICE Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.82% of the float of DICE Therapeutics has been sold short.Short Interest Ratio / Days to CoverDICE Therapeutics has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in DICE Therapeutics has recently increased by 13.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDICE Therapeutics does not currently pay a dividend.Dividend GrowthDICE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DICE. Previous Next 3.8 News and Social Media Coverage News SentimentDICE Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for DICE Therapeutics this week, compared to 1 article on an average week.Search Interest11 people have searched for DICE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added DICE Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DICE Therapeutics insiders have bought 2,753.47% more of their company's stock than they have sold. Specifically, they have bought $8,289,331.00 in company stock and sold $290,500.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of DICE Therapeutics is held by insiders.Percentage Held by Institutions91.51% of the stock of DICE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DICE Therapeutics are expected to decrease in the coming year, from ($2.70) to ($3.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DICE Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DICE Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDICE Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DICE Therapeutics (NASDAQ:DICE) StockDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.Read More Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Stock News HeadlinesMarch 23, 2023 | finance.yahoo.comDICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceMarch 22, 2023 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed DICE Therapeutics (DICE)March 28, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 22, 2023 | americanbankingnews.comDICE Therapeutics (NASDAQ:DICE) Shares Down 6.8% March 22, 2023 | americanbankingnews.comInsider Selling: DICE Therapeutics, Inc. (NASDAQ:DICE) Director Sells 10,000 Shares of StockMarch 22, 2023 | americanbankingnews.comDICE Therapeutics, Inc. (NASDAQ:DICE) Expected to Earn Q1 2023 Earnings of ($0.58) Per ShareMarch 21, 2023 | americanbankingnews.comDICE Therapeutics, Inc. (NASDAQ:DICE) Expected to Earn Q2 2023 Earnings of ($0.64) Per ShareMarch 19, 2023 | americanbankingnews.comDICE Therapeutics (NASDAQ:DICE) Earns "Buy" Rating from HC WainwrightMarch 28, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 17, 2023 | markets.businessinsider.comH.C. Wainwright Releases a Buy Rating on Dice Therapeutics (DICE)March 17, 2023 | americanbankingnews.comSVB Leerink Comments on DICE Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:DICE)March 17, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for DICE Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:DICE)March 16, 2023 | finanznachrichten.deDICE Therapeutics, Inc.: DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsMarch 15, 2023 | finance.yahoo.comDICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsMarch 1, 2023 | msn.comCowen & Co. Initiates Coverage of DICE Therapeutics (DICE) with Outperform RecommendationMarch 1, 2023 | finance.yahoo.comDICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual MeetingFebruary 28, 2023 | msn.comCalifornia's COVID-19 emergency to end 3 years since stay-at-home orders were first issuedFebruary 20, 2023 | marketwatch.comDNA-Encoded Library Market is Booming in Near Future 2023-2028February 8, 2023 | finance.yahoo.comDICE Therapeutics to Participate at Upcoming Investor ConferencesJanuary 4, 2023 | finance.yahoo.comDICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | nasdaq.comAre Medical Stocks Lagging DICE Therapeutics (DICE) This Year?November 24, 2022 | finance.yahoo.comWall Street Analysts Think DICE Therapeutics, Inc. (DICE) Could Surge 93%: Read This Before Placing a BetNovember 15, 2022 | markets.businessinsider.comWhere DICE Therapeutics Stands With AnalystsNovember 14, 2022 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Mereo Biopharma Group Plc (MREO), Jazz Pharmaceuticals (JAZZ)November 9, 2022 | finance.yahoo.comDICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent HighlightsNovember 4, 2022 | finance.yahoo.comDICE Therapeutics to Present at Upcoming Investor ConferencesOctober 21, 2022 | finance.yahoo.comSplunk and Cognyte Stock See Action From Activist InvestorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Company Calendar Last Earnings11/12/2021Today3/27/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.86 High Stock Price Forecast$77.00 Low Stock Price Forecast$54.00 Forecasted Upside/Downside+139.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.95% Return on Assets-22.28% Debt Debt-to-Equity RatioN/A Current Ratio38.14 Quick Ratio38.14 Sales & Book Value Annual Sales$1.13 million Price / Sales1,159.40 Cash FlowN/A Price / Cash FlowN/A Book Value$11.89 per share Price / Book2.31Miscellaneous Outstanding Shares47,710,000Free Float45,659,000Market Cap$1.31 billion OptionableNot Optionable Beta0.71 Key ExecutivesDr. J. Kevin Judice Ph.D. (Age 58)Founder, CEO & Director Comp: $765.04kMr. Scott RobertsonChief Bus. & Financial OfficerDr. Timothy Lu M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $660.44kDr. John R. Jacobsen Ph.D. (Age 54)Chief Scientific Officer Ms. Mary Riley J.D.Gen. CounselMr. Venkat Thalladi Ph.D.Sr. VP of CMCMr. Paul FathereeSr. VP of Medicinal ChemistryMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHDynavax TechnologiesNASDAQ:DVAXDay One BiopharmaceuticalsNASDAQ:DAWNTravere TherapeuticsNASDAQ:TVTXLigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 2,930 shares on 3/23/2023Ownership: 0.040%James Paul ScopaSold 10,000 sharesTotal: $290,500.00 ($29.05/share)Voya Investment Management LLCBought 18,074 shares on 2/28/2023Ownership: 0.061%Parallax Volatility Advisers L.P.Sold 10,000 shares on 2/27/2023Ownership: 0.000%Alliancebernstein L.P.Bought 800 shares on 2/16/2023Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions DICE Stock - Frequently Asked Questions Should I buy or sell DICE Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DICE shares. View DICE analyst ratings or view top-rated stocks. What is DICE Therapeutics' stock price forecast for 2023? 8 equities research analysts have issued 1-year target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $54.00 to $77.00. On average, they expect the company's stock price to reach $65.86 in the next twelve months. This suggests a possible upside of 139.8% from the stock's current price. View analysts price targets for DICE or view top-rated stocks among Wall Street analysts. How have DICE shares performed in 2023? DICE Therapeutics' stock was trading at $31.20 at the beginning of the year. Since then, DICE shares have decreased by 12.0% and is now trading at $27.46. View the best growth stocks for 2023 here. Are investors shorting DICE Therapeutics? DICE Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 6,850,000 shares, an increase of 13.2% from the February 28th total of 6,050,000 shares. Based on an average daily trading volume, of 459,000 shares, the short-interest ratio is presently 14.9 days. Currently, 17.8% of the shares of the stock are short sold. View DICE Therapeutics' Short Interest. When is DICE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our DICE earnings forecast. How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77. What ETFs hold DICE Therapeutics' stock? ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). When did DICE Therapeutics IPO? (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. What is DICE Therapeutics' stock symbol? DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE." Who are DICE Therapeutics' major shareholders? DICE Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (14.37%), Price T Rowe Associates Inc. MD (6.75%), Sands Capital Ventures LLC (5.77%), Avoro Capital Advisors LLC (5.30%), Driehaus Capital Management LLC (4.10%) and Alkeon Capital Management LLC (2.18%). Insiders that own company stock include James Paul Scopa and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of DICE Therapeutics? Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DICE Therapeutics' stock price today? One share of DICE stock can currently be purchased for approximately $27.46. How much money does DICE Therapeutics make? DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.31 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. How can I contact DICE Therapeutics? DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com. This page (NASDAQ:DICE) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.